SAN DIEGO, Jan. 30, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to review its financial results for the quarter ended March 31, 2020 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 3387116.

SAN DIEGO, Feb. 27, 2020 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update. As a result of the COVID-19 pandemic, these are unprecedented times, circumstances are rapidly evolving, both from a macroeconomic perspective and in our industry, and we will continue to assess our circumstances and development timelines.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

SAN DIEGO, March 24, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, a division of the National Institutes of Health (NIH). The NIH issued this final notice of award for the PCT project after reviewing data from the completed PCT clinical study and commercialization plans for Ovaprene, an investigational hormone-free, monthly contraceptive.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms and conditions of the purchase agreement, Daré will have the right, from time to time and at its sole discretion, to sell up to $15 million of its stock to LPC over a 36-month period, subject to a registration statement covering the resale by LPC of shares issued and sold under the purchase agreement being filed and declared effective by the Securities and Exchange Commission (“SEC”) and satisfaction of the other conditions in the purchase agreement.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, today announced that the companies have signed a partnership agreement under which Health Decisions will exclusively provide CRO services within the United States to support the clinical development of Daré’s innovative pipeline of novel programs designed specifically to address persistent unmet needs in the areas of contraception, fertility, and broader gynecological disorders. Daré and Health Decisions have successfully worked together on prior Daré clinical studies, including the post-coital test clinical study of Ovaprene®.

Q1 2020 Dare Bioscience Inc Earnings Call

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b). As a result, all previously reported Nasdaq compliance matters have been resolved and the previously-scheduled hearing before the Nasdaq Hearings Panel has been canceled. “We believe that 2020 will be a transformational year for Daré,” said Sabrina Martucci Johnson, President and CEO of Daré.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update. “The first quarter was an active one for Daré, beginning with the commercial licensing agreement with Bayer for Ovaprene and continuing with important progress in advancing the development of each of our later-stage product candidates,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. In addition, we currently believe that we will be able to report topline data for our planned Phase 2b study of Sildenafil Cream, 3.6% in female sexual arousal disorder in 2021 and topline data for our planned pivotal contraceptive study of Ovaprene in 2022.

Q4 2019 Dare Bioscience Inc Earnings Call

Anika Therapeutics, Inc. (ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchard’s appointment, the previously announced interim Office of the President has been dissolved. “We are pleased that Dr. Blanchard, a seasoned executive who has previously served as a biotech President and CEO, has agreed to step in as our interim CEO as we search for Anika’s next leader,” said Dr. Joseph Bower, Chairman of Anika's Board of Directors.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in healthy women. Female Sexual Arousal Disorder (FSAD), a condition characterized primarily by an inability to attain or maintain sufficient genital arousal during sexual activity, is analogous to erectile dysfunction (ED) in men, and sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men.

SAN DIEGO, Feb. 05, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief.

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Dare Bioscience Inc (NASDAQ:DARE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 4:30 ...

Daré Bioscience, Inc.(DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. During the panel discussion, Ms. Johnson will share insights from the Company’s DARE-BV1 development program. DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2%, is an investigational product for the treatment of bacterial vaginosis (BV), one of the most common vaginal infections.

Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DARE-BV1 for the treatment of bacterial vaginosis (BV) in women. DARE-BV1 was previously granted Qualified Infectious Disease Product (QIDP) designation for the treatment of BV in August 2019.

Anyone researching Daré Bioscience, Inc. (NASDAQ:DARE) might want to consider the historical volatility of the share...